Effectiveness and safety of ranibizumab in patients with central retinal vein occlusion: results from the real-world, global, LUMINOUS study.
Journal
Eye (London, England)
ISSN: 1476-5454
Titre abrégé: Eye (Lond)
Pays: England
ID NLM: 8703986
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
received:
14
12
2020
accepted:
15
07
2021
revised:
13
07
2021
pubmed:
31
7
2021
medline:
27
7
2022
entrez:
30
7
2021
Statut:
ppublish
Résumé
To evaluate the effectiveness, treatment patterns and long-term safety of ranibizumab 0.5 mg in treatment-naïve patients with central retinal vein occlusion (CRVO) in a real-world setting. LUMINOUS, a 5-year, global, prospective, multicentre, multi-indication, observational, open-label study, recruited treatment naïve or prior treated patients who were treated as per the local ranibizumab label. Here, we report the mean change in visual acuity (VA; Early Treatment Diabetic Retinopathy Study [ETDRS] letters), treatment exposure over year (Y) 1 and 5-year safety in treatment-naïve CRVO patients. At baseline, the mean age of treatment-naïve CRVO patients (n = 327) was 68.9 years, with a mean (Standard deviation [SD]) VA of 40.6 (23.9) letters. At Y1, patients (n = 144) had a mean (SD) VA gain from baseline of 10.8 (19.66) letters, with a mean (SD) of 5.4 (2.65) ranibizumab injections. Patients demonstrated mean (SD) VA gains of 2.7 (19.35), 11.6 (20.56), 13.9 (18.08), 11.1 (18.46) and 8.2 (24.86) letters with 1, 2-3, 4-5, 6-8 and >8 ranibizumab injections, respectively. Mean (SD) VA gains at Y1 in patients receiving loading (67.4%) and no loading dose (32.6%) was 11.9 (20.42) and 8.4 (17.99) letters, respectively. Over five years, the incidence of ocular/non-ocular adverse events (AEs) and serious AEs was 11.3%/8.6% and 1.2%/6.7%, respectively. These results demonstrate the effectiveness of ranibizumab in treatment-naïve CRVO patients at Y1 with clinically meaningful VA gains and no new safety findings over five years. These findings may help inform routine practice and enable better clinical management to achieve optimal visual outcomes.
Identifiants
pubmed: 34326500
doi: 10.1038/s41433-021-01702-y
pii: 10.1038/s41433-021-01702-y
pmc: PMC9307792
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Ranibizumab
ZL1R02VT79
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
1656-1661Informations de copyright
© 2021. The Author(s).
Références
Rogers S, McIntosh RL, Cheung N, Lim L, Wang JJ, Mitchell P, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010;117:313–9.e1.
doi: 10.1016/j.ophtha.2009.07.017
Laouri M, Chen E, Looman M, Gallagher M. The burden of disease of retinal vein occlusion: review of the literature. Eye(Lond). 2011;25:981–8.
Rhoades W, Dickson D, Nguyen QD, Do DV. Management of macular edema due to central retinal vein occlusion—the role of aflibercept. Taiwan J Ophthalmol. 2017;7:70–6.
doi: 10.4103/tjo.tjo_9_17
Braithwaite T, Nanji AA, Lindsley K, Greenberg PB. Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion. Cochrane database Syst Rev. 2014;5:Cd007325.
Campochiaro PA. Anti-vascular endothelial growth factor treatment for retinal vein occlusions. Ophthalmologica.2012;227:30–5.
doi: 10.1159/000337157
Gerding H, Monés J, Tadayoni R, Boscia F, Pearce I, Priglinger S. Ranibizumab in retinal vein occlusion: treatment recommendations by an expert panel. Br J Ophthalmol. 2015;99:297–304.
doi: 10.1136/bjophthalmol-2014-305041
Adelman RA, Parnes AJ, Bopp S, Saad Othman I, Ducournau D. Strategy for the management of macular edema in retinal vein occlusion: the European VitreoRetinal Society macular edema study. Biomed Res Int. 2015;2015:870987.
pubmed: 25705695
pmcid: 4325227
Channa R, Smith M, Campochiaro PA. Treatment of macular edema due to retinal vein occlusions. Clin Ophthalmol. 2011;5:705–13.
pubmed: 21629578
pmcid: 3104801
Larsen M, Waldstein SM, Boscia F, Gerding H, Monés J, Tadayoni R, et al. Individualized ranibizumab regimen driven by stabilization criteria for central retinal vein occlusion: twelve-month results of the CRYSTAL study. Ophthalmology. 2016;123:1101–11.
doi: 10.1016/j.ophtha.2016.01.011
Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117:1124–33.e1.
doi: 10.1016/j.ophtha.2010.02.022
Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, Saroj N, et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology. 2011;118:2041–9.
doi: 10.1016/j.ophtha.2011.02.038
Scott IU, Figueroa MJ, Oden NL, Ip MS, Blodi BA, VanVeldhuisen PC. SCORE2 report 5: vision-related function in patients with macular edema secondary to central retinal or hemiretinal vein occlusion. Am J Ophthalmol. 2017;184:147–56.
doi: 10.1016/j.ajo.2017.10.008
Babiuch AS, Han M, Conti FF, Wai K, Silva FQ, Singh RP. Association of disorganization of retinal inner layers with visual acuity response to anti-vascular endothelial growth factor therapy for macular edema secondary to retinal vein occlusion. JAMA Ophthalmol. 2019;137:38–46.
doi: 10.1001/jamaophthalmol.2018.4484
Madanagopalan VG, Kumari B. Predictive value of baseline biochemical parameters for clinical response of macular edema to bevacizumab in eyes with central retinal vein occlusion: a retrospective analysis. Asia Pac J Ophthalmol (Phila). 2018;7:321–30.
Nghiem-Buffet S, Baillif S, Regnier S, Skelly A, Yu N, Sodi A. Treatment patterns of ranibizumab intravitreal injection and dexamethasone intravitreal implant for retinal vein occlusion in the USA. Eye (Lond). 2017;31:551–9.
doi: 10.1038/eye.2016.269
Vaz-Pereira S, Marques IP, Matias J, Mira F, Ribeiro L, Flores R. Real-world outcomes of anti-VEGF treatment for retinal vein occlusion in Portugal. Eur J Ophthalmol. 2017;27:756–61.
doi: 10.5301/ejo.5000943
Winterhalter S, Eckert A, Vom Brocke GA, Schneider A, Pohlmann D, Pilger D, et al. Real-life clinical data for dexamethasone and ranibizumab in the treatment of branch or central retinal vein occlusion over a period of six months. Graefes Arch Clin Exp Ophthalmol. 2018;256:267–79.
doi: 10.1007/s00417-017-3852-1
European Medicines Agency. Lucentis
Epstein M. Guidelines for good pharmacoepidemiology practices (GPP). Pharmacoepidemiol Drug Saf. 2005;14:589–95.
doi: 10.1002/pds.1082
ClinicalTrials.gov. Observe the effectiveness and safety of Ranibizumab in real life setting (LUMINOUS). Available at: https://clinicaltrials.gov/ct2/show/NCT01318941 . Accessed on 26 July, 2021.
Mitchell P, Sheidow TG, Farah ME, Mahmood S, Minnella AM, Eter N, et al. Effectiveness and safety of ranibizumab 0.5 mg in treatment-naïve patients with diabetic macular edema: results from the real-world global LUMINOUS study. PloS ONE. 2020;15:e0233595.
doi: 10.1371/journal.pone.0233595
Koh A, Lai TYY, Wei WB, Mori R, Wakiyama H, Park KH, et al. Real-world effectiveness and safety of ranibizuma treatment in patients with and without polyploidal choroidal vasculopathy: twelve-month results from the LUMINOUS study. Retina (Philadelphia, Pa). 2020;40:1529–39.
doi: 10.1097/IAE.0000000000002624
Holz FG, Figueroa MS, Bandello F, Yang Y, Ohji M, Dai H, et al. Ranibizumab treatment in treatment-naive neovascular age-related macular degeneration: results from LUMINOUS, a global real-world study. Retina (Philadelphia, Pa). 2020;40:1673–85.
doi: 10.1097/IAE.0000000000002670
Hamilton RD, Clemens A, Minnella AM, Lai TYY, Dai H, Sakamoto T, et al. Real-world effectiveness and safety of ranibizumab for the treatment of myopic choroidal neovascularization: results from the LUMINOUS study. PloS ONE. 2020;15:e0227557.
doi: 10.1371/journal.pone.0227557
Campochiaro PA, Sophie R, Pearlman J, Brown DM, Boyer DS, Heier JS, et al. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology. 2014;121:209–19.
doi: 10.1016/j.ophtha.2013.08.038
Heier JS, Campochiaro PA, Yau L, Li Z, Saroj N, Rubio RG, et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology. 2012;119:802–9.
doi: 10.1016/j.ophtha.2011.12.005
Sagkriotis A, Chakravarthy U, Griner R, Doyle O, Wintermantel T, Clemens A. Application of machine learning methods to bridge the gap between non-interventional studies and randomized controlled trials in ophthalmic patients with neovascular age-related macular degeneration. Contemp Clin Trials. 2021;104:106364.
doi: 10.1016/j.cct.2021.106364
Ziemssen F, Feltgen N, Holz FG, Guthoff R, Ringwald A, Bertelmann T, et al. Demographics of patients receiving Intravitreal anti-VEGF treatment in real-world practice: healthcare research data versus randomized controlled trials. BMC Ophthalmol. 2017;17:7.
doi: 10.1186/s12886-017-0401-y
Callizo J, Ziemssen F, Bertelmann T, Feltgen N, Vögeler J, Koch M, et al. Real-world data: ranibizumab treatment for retinal vein occlusion in the OCEAN study. Clin Ophthalmol (Auckland, NZ). 2019;13:2167–79.
doi: 10.2147/OPTH.S209253
Kim SJ, Yoon YH, Kim HK, Yoon HS, Kang SW, Kim JG, et al. Baseline predictors of visual acuity and retinal thickness in patients with retinal vein occlusion. J Korean Med Sci. 2015;30:475–82.
doi: 10.3346/jkms.2015.30.4.475
Arias L, Armadá F, Donate J, García-Arumí J, Giralt J, Pazos B, et al. Delay in treating age-related macular degeneration in Spain is associated with progressive vision loss. Eye (Lond). 2009;23:326–33.
doi: 10.1038/sj.eye.6703053
Bressler SB, Qin H, Beck RW, Chalam KV, Kim JE, Melia M, et al. Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab. Arch Ophthalmol. 2012;130:1153–61.
doi: 10.1001/archophthalmol.2012.1107
Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013;120:2013–22.
doi: 10.1016/j.ophtha.2013.02.034
Williams TA, Blyth CP. Outcome of ranibizumab treatment in neovascular age related macula degeneration in eyes with baseline visual acuity better than 6/12. Eye (Lond). 2011;25:1617–21.
doi: 10.1038/eye.2011.224
Oliver-Fernandez A, Bakal J, Segal S, Shah GK, Dugar A, Sharma S. Progression of visual loss and time between initial assessment and treatment of wet age-related macular degeneration. Can J Ophthalmol. 2005;40:313–9.
doi: 10.1016/S0008-4182(05)80074-2
Kaiser PK, Brown DM, Zhang K, Hudson HL, Holz FG, Shapiro H, et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol. 2007;144:850–7.
doi: 10.1016/j.ajo.2007.08.012
Boyer DS, Antoszyk AN, Awh CC, Bhisitkul RB, Shapiro H, Acharya NR. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2007;114:246–52.
doi: 10.1016/j.ophtha.2006.10.045
Thach AB, Yau L, Hoang C, Tuomi L. Time to clinically significant visual acuity gains after ranibizumab treatment for retinal vein occlusion: BRAVO and CRUISE trials. Ophthalmology. 2014;121:1059–66.
doi: 10.1016/j.ophtha.2013.11.022